Business Wire

ANT-GROUP

20.5.2021 09:39:09 CEST | Business Wire | Press release

Share
Ant Group Publishes its 2020 Sustainability Report: Building a Better World Together

Ant Group today released its 2020 Sustainability Report, highlighting its key activities, achievements and progress in bringing inclusive development and environmental sustainability to the world through digital technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005402/en/

In 2020, Covid-19 transformed the way people live and work. The report outlines Ant’s efforts to support Small and Micro Enterprises (SMEs) in their pandemic recovery, strengthen financial inclusion, bridge digital inequality, and promote sustainability.

“Ant Group remains committed to its mission of using technology to provide ordinary people and small businesses with more equal access to financial and daily life services,” said Ant Group’s Chairman and Chief Executive Officer Eric Jing. “As we face the challenges of today, we feel an even greater sense of responsibility and will strive to explore better solutions to serve the development of society.”

Working with its partners, Ant Group is continuing to build a future that is more inclusive, green, and sustainable, by reducing financing costs for SMEs and micro businesses and developing rural economies, investing in green technologies, and working to further protect the interests of consumers.

Key highlights from the 2020 Sustainability Report are enclosed below.

Supporting Small and Micro Enterprises

In 2020, MYbank, a leading online private commercial bank and an associate of Ant Group, served 35 million SMEs and individually-owned businesses, of which 80% were first-time borrowers of any business loans, while keeping the default rate at a low level.

MYbank’s initiatives to support SMEs’ pandemic recovery included:

  • Providing low-interest and interest-free loans to 8.5 million digital shops and small stores in Hubei Province.
  • Issuing RMB 10 billion in interest-free loan vouchers to businesses in 81 Chinese cities to support the recovery of small shops.
  • Offering a free "zero-billing period" on advance payment services to e-commerce businesses, providing advance payments of more than RMB 200 billion

Adopting and Encouraging Green Initiatives

  • In 2021, Ant announced its carbon neutrality goals and corresponding action plans, pledging to achieve carbon neutrality by 2030.
  • The company also put forward a series of intermediary goals, including a 30% reduction in absolute emissions in Scope 1 and Scope 2 by 2025 (compared with 2020), a full assessment of its supply chain emissions, and a full transition to renewable energy for its leased data center services. Ant Forest, a tree-planting mini program in the Alipay app where users earn points for making low-carbon lifestyle choices, attracted over 550 million users to plant more than 220 million real trees, helping reduce carbon emissions by more than 12 million tons as of December 2020.

Creating Opportunities for Women

  • Launched in late 2019, Ant’s A-Idol Initiative brought employment opportunities to women in less-developed areas, with women accounting for at least 60% of the employees of social enterprises incubated by the initiative.
  • As part of its "Wind Rider” project, Ant funded 40 women’s football teams in rural schools to provide women with more opportunities for education and personal development through football.
  • On July 15, 2020, Ant launched the "Cyber Mulan" program, which aims to assist 50 million women globally within five years, enhancing women's participation and competitiveness in the digital economy.

Access the full report here: https://www.antgroup.com/en/news-media/media-library?type=Sustainability%20Report

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. Ant Group strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye